SQZBOTCHealthcare · Biotechnology

SQZ Biotechnologies Company

$0.02+0.00%(+$0.00)

TickerSpark Score

47/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SQZB research report →

52-Week Range2% of range

Low $0.02

Current $0.02

High $0.07

Companywww.sqzbiotech.com

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.

CEO: Lawrence J. Knopf
IPO: 2020
Employees: 53
HQ: Watertown, MA, US

Price Chart

-14.29% · this period

Valuation

Market Cap: $707.79K
P/E: -0.01
P/S: 0.03
P/B: 0.01
EV/EBITDA: 0.45
Div Yield: 0.00%

Profitability

Gross Margin: 46.57%
Op Margin: -383.68%
Net Margin: -377.88%
ROE: -87.75%
ROIC: -81.66%

Growth & Income

Revenue: $21.03M · -22.40%
Net Income: $-79,464,000 · -15.60%
EPS: $-2.76 · -10.84%
Op Income: $-80,684,000
FCF YoY: -1.60%

Performance & Tape

52W High: $0.07
52W Low: $0.02
50D MA: $0.02
200D MA: $0.03
Beta: 0.33
Avg Volume: 5.91K

Get TickerSpark's AI analysis on SQZB

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime